Attention Administrator - database is in test mode!
Cannabidiol Does Not Convert to THC In Vivo
Although CBD Can Be Transformed to THC Under Acidic Conditions, the Conversion of Oral CBD Doesn’t Occur In Vivo
GEN Roundup: Top Trends in Tissue Engineering
The Ideal of Tissue Engineering Is Becoming More of a Reality
Human Neural Stem Cell Therapy for Chronic Ischemic Stroke
Charting Progress from Laboratory to Patients
Considering Sex as a Biological Variable in Biomedical Research
Factoring Sex into Research Designs, Analyses, and Scientific Study Reports
As the new administration considers the future direction of the Food and Drug Administration, a group of researchers has created a Blueprint for Transparency at the agency to advance the development of safe and effective new products. They published an overview of the Blueprint in JAMA that makes 18 recommendations in five principal areas:
The FDA should 1) disclose more information about key milestones in the application process; 2) disclose more of its own analysis and decision-making; 3) disclose more about the application and review process for generic drugs and follow-on biologics.4) disclose data from scientific studies to enhance understanding of medical products; and 5) correct misleading information in the market.